Introduction {#s1}
============

Sustained interferon type I (IFN-I) production by activated dendritic cells (DCs) is widely regarded as a common driver of autoimmune (AI) syndromes in humans and mice ([@B1]). Under aseptic conditions, some DCs produce IFN-I when they sense damage associated molecular patterns (DAMPs) such as DNA. A critical role for tissue DNA as an autoimmune trigger emerged in mice lacking DNA catabolizing enzymes, which succumbed to spontaneous, lethal autoimmunity due to sustained cytosolic DNA sensing to activate the signaling adaptor Stimulator of Interferon Genes (STING), a potent IFNβ inducer ([@B2], [@B3]). The paradigm that DNA sensors incite immunity via STING/IFN-I signaling was also reinforced by reports showing that cyclic dinucleotides (CDNs), which bind and activate STING, incited robust anti-tumor immunity ([@B4]). Consequently, STING agonists have emerged as promising adjuvants to treat infections and cancer.

On the other hand, IFN-I also induces specialized DC subsets to express indoleamine 2,3 dioxygenase (IDO), which acquire potent T cell regulatory functions due to increased tryptophan (Trp) metabolism ([@B5]). IDO activity is commonly elevated at sites of chronic inflammation associated with AI disease, suggesting that IFN-I signaling may have diametric roles in regulating, as well as promoting autoimmunity. Consistent with this paradigm, STING/IFN-I signaling slowed autoimmune lupus disease progression in susceptible MRL^lpr^ mice and promoted tumor growth ([@B6]--[@B8]). Moreover, cargo DNA released by DNA nanoparticles (DNPs) and CDNs alleviated experimentally induced autoimmune encephalitis (EAE) and arthritis in mice by stimulating STING/IFN-I signaling to induce IDO1 gene expression ([@B9], [@B10]). Increased IDO activity suppresses immunity by depleting tryptophan (Trp) to activate GCN2 stress responses and generating immune suppressive Trp metabolites, some of which stimulate aryl hydrocarbon receptor (AhR) signaling ([@B11]). Therapeutic responses to DNPs and apoptotic cells were dependent on STING/IFN-I signaling to induce IDO in specific DC subsets to suppress effector T cell responses ([@B12]). Thus, STING/IFN-I signaling incites diametric immune responses in distinct settings of disease and therapy. Here we show that therapeutic responses to DNPs in the EAE model depend on the cytosolic DNA sensor cGAS and the PD-1/PD-L pathway. Moreover, DNP treatments to activate STING were more effective and durable when combined with drugs that modify Trp metabolism downstream of IDO.

Materials and Methods {#s2}
=====================

Mice and Induction of EAE
-------------------------

C57BL/6J (B6) and PD1-deficient (PD1-KO) mice were obtained from Jackson Laboratories, PD-L2-KO, PD-L1/2-KO were kindly provided by Arlene Sharpe (Harvard Medical School, MA, USA) and cGAS-KO mice were kindly provided by Herbert (Skip) Virgin (Washington University, St. Louis, MO). Mice were bred under specific pathogen-free conditions at Augusta University, USA or at Newcastle University, UK. ARRIVE guidelines were followed to minimize the number of animals used.

EAE Induction and Treatments
----------------------------

To induce EAE, mice (age 8--12 wk) were immunized at two sites on rear flanks with myelin oligodendrocyte glycoprotein peptide MEVGWYRSPFSRVVHLYRNGK (MOG~35−55~; 100 μg, s/c, Bio Basic Canada) emulsified in CFA (Difco Laboratories, Detroit, MI) containing 4 mg/ml *Mycobacterium tuberculosis* H37Ra (Difco Laboratories). Pertussis toxin (PTX, 200 ng; Sigma-Aldrich) was given (i/p) on days 0 and 2 after immunization. Clinical symptoms of EAE were scored on a scale from 0 to 5 as follows: 0, no clinical signs; 0.5, partial limp tail; 1, full limp tail or waddling gait; 1.5, limp tail and waddling gait/lumbar weakness; 2, partial paralysis of one hindlimb; 2.5, paralysis of one hindlimb or partial paralysis of both hindlimbs; 3, paralysis of one hindlimb and partial paralysis of the other hindlimb; 4, paralysis of both hindlimbs; 5, complete paralysis of both hindlimbs and weakness of the upper limb/three paralyzed limbs/moribund state (\>20% weight loss and/or complete hind paralysis with hyperventilation and urinary incontinence) or dead. By disease onset groups of mice received intravenous injections of DNPs (prepared by mixing 7 μl of 150 mM linear polyethylenimine, PEI, from Sigma, with 21 μg CpG^free^ LacZ pDNA in 200 μl 5% glucose solution, N/P = 16.7), or cyclic guanylate (2′,5′) monophosphate/adenosine (3′,5′) monophosphate (cGAMP; Invivogen; 100 μg/200 ul saline) or vehicle treatments. Some mice received the following drugs; Kat II inhibitor, PF-04859989 (Sigma, given daily from day 11--22, 40 mg/kg, i/p), AhR inhibitor CH-223191 (Sigma; 5 mg/kg, i/p given 1 h before each cGAMP injection), HAAO inhibitor, 4-chloro-3-hydroxyanthranilic acid (Enamine given daily from day 11--21, 125 mg/kg, i/p).

IDO Enzyme Assay
----------------

IDO activity was measured by high performance liquid chromatography (HPLC) as described ([@B13]). Briefly, cells were harvested, lysed (2 × freeze/thaw) and incubated in substrate mixture (100 mM potassium phosphate buffer pH = 6 containing 50 uM methylene blue, 50 mM ascorbate, 0.4 mM L-Tryptophan, 20 ug catalase; all from Sigma) for 0 or 2 h at 37°C. Reaction was stopped and protein precipitated with 1:10 perchloric acid 60% (Sigma); samples were centrifuged, filtered, and the kynurenine levels measured by HPLC. Results are expressed as pmol of kynurenine (\[2 h\]-\[0\])/hour/mg of protein.

FACS Staining
-------------

Splenocyte suspensions were stained in PBS with antibodies against the surface markers CD11c (clone N418, eBioscience), CD11b (clone M1/70, Biolegend), or CD19 (clone 1D3, BD horizon), PD-L1 (clone 10F.9G2, BD horizon). After washing with PBS, flow cytometric analyses were performed using a Fortessa X20 cytometer (BD Biosciences), and data generated were analyzed using FACSDiva (BD Biosciences) or FlowJo (Tree Star, Ashland, OR) software. All antibody dilutions were used as per manufacture\'s instruction.

Extraction of Kynurenine Pathway Metabolites From Tissue Samples
----------------------------------------------------------------

Mouse brain/spleen tissue samples were suspended in ice-cold 0.32 M sucrose solution (\~500 μL solution/100 mg tissue) in sterile 2 mL Eppendorf tubes. Tissue samples were maintained on ice throughout the homogenization protocol. Two homogenization beads were added to each sample and the samples disrupted using a TissueLyser instrument (Qiagen) for 2 min at 25 shakes/second. Homogenate samples were centrifuged at 13,000 rpm for 3 min before the supernatant was transferred to a fresh Eppendorf tube. Samples were centrifuged and transferred again, as above. The total protein concentration in each tissue homogenate sample was determined using a Pierce BCA Protein Assay Kit, according to the manufacturer\'s protocol. Further adjustments to tissue homogenate dilution/concentration were made using ice-cold 0.32M sucrose solution.

Analysis of Kynurenine Pathway Metabolites by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
-------------------------------------------------------------------------------------------------------

Biological sample (100 μL; serum or diluted homogenate) were diluted with 4% phosphoric acid (100 μL). A calibration curve for each metabolite was prepared over ranges (0.05--100 ng) to determine metabolite concentrations. Samples and calibration standards were spiked with internal standard (d5-tryptophan) and loaded onto individual wells of a Waters 96-well array HLB solid phase extraction plate pre-conditioned with methanol (500 μL) and water (500 μL). Samples were washed with water (500 μL) and eluted with 70% methanol (200 μL). Reduced to dryness and resuspended in 30% methanol (70 μL). Using a Shimadzu Nexera UPLC system, 10 μL of each sample well was injected (20 μL) onto an ACE C18-PFP (100 mm × 2.1 mm, 1.7 μm, ACT Technologies, Aberdeen, UK) coupled to an ABSciex QTRAP 6500+ mass analyzer operated in polarity switching electrospray mode. Flow rate was set at 0.5 mL/min at 40 °C. A water:methanol gradient (both containing 0.1% formic acid) was used for separation, with the following conditions: 90:10 water:methanol to 20:80 over 6 min, followed by re-equilibration to 80:20. The total run time was 9 min. Analyst quantitation software (ABI Sciex) was used to acquire and process the data, following European Medicines Agency method validation guidelines for accuracy, precision and limits of detection.

Statistical Analysis
--------------------

Statistical significance for EAE clinical scores were evaluated with two-way ANOVA, and normality checks were carried out on the residuals which were approximately normally distributed. The unpaired Student *t*-test was used for the remaining statistical evaluations after normality was verified by the Shapiro-Wilk test. Two-tailed *p* values \< 0.05 were considered significant. Data represent mean ± SEM. GraphPad Prism was used to perform all data analyses.

Study Approval
--------------

All procedures were approved by the local Institutional Animal Care and Use Committee in Augusta University and the UK Home Office (Project license P1B4042BB).

Results {#s3}
=======

Therapeutic Responses to DNPs Depend on cGAS
--------------------------------------------

As we reported previously, systemic (i/v) DNP administration elevated IDO activity in many mouse tissues ([@B9]). DNPs did not induce IDO activity in spleens from mice lacking the cytosolic DNA sensor cGAS ([Figure 1A](#F1){ref-type="fig"}). Consistent with this finding, DNP treatment from EAE onset (11 days after MOG immunization until day 21) had no significant effect on EAE progression, while cGAS ablation had no effect on EAE progression *per se* ([Figure 1B](#F1){ref-type="fig"}). As expected, DNPs reduced EAE clinical scores in B6 mice significantly until experimental endpoints at day 25. Thus, DNP cargo DNA is sensed by cGAS to induce tolerogenic responses that attenuate EAE progression.

![The DNA sensor cGAS mediates therapeutic responses to DNPs that suppress EAE. **(A)** IDO activity in spleens from WT and cGAS-KO (KO) mice treated with DNPs. **(B)** EAE was induced in B6 (WT) and cGAS-KO mice (see section Materials and Methods), and EAE progression was monitored and scored. Experimental groups (*n* = 10) were treated with DNPs (every other day from day 11--21) and control WT mice were treated with vehicle (glucose 5%). Data were analyzed by *t*-test for **(A)** and two-way ANOVA for **(B)**. Experiments were repeated once. NS, not significant; \*\*\**p* \< 0.001, ^\#^*p* \< 0.0001.](fimmu-11-01256-g0001){#F1}

Therapeutic Responses to STING Agonists Depend on the PD-1/PD-L Pathway
-----------------------------------------------------------------------

The PD-1/PD-L pathway is required for tolerogenic DCs expressing IDO1 to activate Foxp3-lineage regulatory CD4 T cells (Tregs), which then suppress effector T cell responses via a mechanism dependent on PD-1/PD-L signaling ([@B14], [@B15]). To test if the PD-1/PD-L pathway was required for therapeutic responses to DNPs, EAE was induced in mice lacking genes encoding PD-1 or its ligands (PD-L1, PD-L2) and mice were treated with DNPs at the time of EAE onset ([Figure 2](#F2){ref-type="fig"}). Ablating PD-1 or its ligands had no significant impact on the kinetics of EAE induction or clinical severity, relative to WT control mice, though EAE progression was slightly slower in PD-L2-KO mice ([Figure 2E](#F2){ref-type="fig"}). PD-1 ablation did not abolish therapeutic responses to DNPs ([Figure 2B](#F2){ref-type="fig"}) but EAE clinical severity was significantly higher (scores 2--3) in DNP-treated PD-1-KO mice ([Figure 2C](#F2){ref-type="fig"}), relative to DNP-treated WT control mice (scores \~1). Moreover, EAE severity in DNP-treated PD-1-KO mice was only slightly lower than in vehicle-treated WT mice (scores 3--4). In contrast, therapeutic responses to DNPs that slowed EAE progression and reduced clinical severity were abolished in mice lacking PD-L1 ([Figure 2D](#F2){ref-type="fig"}), PD-L2 ([Figure 2E](#F2){ref-type="fig"}) or both PD-1 ligands ([Supplemental Figure 1A](#SM1){ref-type="supplementary-material"}). Thus, PD-L1 and PD-L2 have non-redundant roles in mediating tolerogenic responses to DNPs that alleviate EAE.

![Therapeutic responses to DNPs depend on the PD-1/PD-L pathway. **(A--E)** EAE was induced in B6 (WT), PD-1-KO **(B,C)**, PD-L1-KO **(D)**, and PD-L2-KO **(E)** mice, and disease onset and progression was monitored and scored. At EAE onset (day 11) mice were treated with DNPs every other day until day 21 and control mice were treated with vehicle (Vh; glucose 5%). Data were analyzed by two-way ANOVA (NS, not significant; \**p* \< 0.05; \*\*\**p* \< 0.001, ^\#^*p* \< 0.0001) and are representative of 2 experiments with *n* = 6--18. **(F)** B6 (WT), PD-1-KO, PD-L1-KO, PD-L2-KO and PD-L1+L2-KO mice were treated with DNPs or Vh (glucose 5%). Twenty-four hours later spleens were harvested and IDO activity in homogenized tissues was measured by assessing Kyn production *ex vivo*. Kyn levels were significantly higher (*p* \< 0.0001, *n* = 4--9, Student\'s *t*-test) in spleens from all mice treated with DNPs regardless of their genotype, relative to Kyn levels in spleens from vehicle-treated WT mice.](fimmu-11-01256-g0002){#F2}

To test if PD-1/PD-L signaling was required to induce IDO1 in splenic DCs we assessed IDO enzyme activity in spleens of naïve mice with defective PD-1/PD-L pathways 24 h after DNP treatment. Following STING activation, induced IDO activity in spleens of WT mice and mice with defective PD-1/PD-L signaling pathways was significantly higher than basal levels in untreated mice, though induced IDO activity was slightly lower in the absence of functional PD-1/PD-L signaling ([Figure 2F](#F2){ref-type="fig"}). Thus, therapeutic responses to DNP treatment were dependent on IDO induction and PD-1/PD-L signaling but IDO1 induction was not dependent on PD-1/PD-L signaling.

Cyclic 2′3′-guanyl-adenyl monophosphate (cGAMP) is a potent natural STING agonist made when cGAS is activated by DNA in mammalian cells ([@B16]). We tested if synthetic cGAMP treatments incited tolerogenic responses that slow EAE progression. cGAMP treatment from the time of EAE onset (days 11--21) reduced clinical scores significantly until experimental endpoints at day 25 ([Figure 3A](#F3){ref-type="fig"}). As for DNPs, therapeutic responses to cGAMP were abolished in mice lacking PD-1 or PD-L1 genes ([Figures 3B,C](#F3){ref-type="fig"}) or genes encoding both PD-1 ligands ([Supplemental Figure 1B](#SM1){ref-type="supplementary-material"}). In addition, IDO1 induction in spleen was not dependent on PD-1/PD-L signaling after cGAMP treatment to activate STING ([Figure 3D](#F3){ref-type="fig"}).

![The PD-1/PD-L pathway is required for therapeutic responses to cGAMP. **(A--C)** EAE was induced in B6 (WT), PD-1-KO, and PD-L1-KO mice, and disease onset and progression was monitored and scored. At EAE onset (day 11) mice were treated with cGAMP every other day until day 21 and control mice were treated with vehicle (Vh; saline). Data were analyzed by two-way ANOVA (NS, not significant; \#*p* \< 0.0001) and are representative of 2 experiments with *n* = 6--18. **(D)** Mice were treated with cGAMP or Vh (saline) and 24 h later spleens were harvested and IDO activity in homogenized tissues was measured by assessing Kyn production *ex vivo*. Data were analyzed using Student\'s *t*-test and Kyn levels were significantly higher in all mice (*n* = 4--9) treated with cGAMP, B6 (WT, *p* \< 0.001), PD-1-KO (*p* \< 0.0001), PD-L1-KO (*p* \< 0.01), PD-L2-KO (*p* \< 0.05) and PD-L1+L2-KO (*p* \< 0.05) mice relative to basal Kyn levels in vehicle-treated WT mice.](fimmu-11-01256-g0003){#F3}

DNPs Enhance PD-L1 Expression by Splenic APCs
---------------------------------------------

APCs expressing PD-L1 suppress effector T cell responses and stabilize the regulatory functions of Foxp3 in Tregs via PD-1 ([@B17], [@B18]). As EAE induction alters APC phenotypes and numbers we examined splenic APCs from mice treated with vehicle (Vh, 5% glucose) or DNPs 22 days after MOG immunization. DNP treatment stimulated splenic DCs (CD11c^+^) and myeloid (CD11b^+^) cell subsets to up-regulate PD-L1 expression, while B cells remained PD-L1^neg^ ([Figure 4](#F4){ref-type="fig"}). PD-L1 expression increased uniformly on a small population of splenic DCs (CD11c^+^) co-expressing the B cell marker CD19 (CD19^+^ DCs), which also expanded following DNP treatment ([Figure 4B](#F4){ref-type="fig"}). As reported previously, CD19^+^ DCs exhibit hybrid features of both B cells and DCs, and amongst splenic DC subsets, CD19^+^ DCs are uniquely competent to express IDO1 ([@B19]). PD-L1 expression also increased on a subset (\~50%) of conventional (CD19^neg^) DCs, which also expanded after DNP treatment ([Figure 4C](#F4){ref-type="fig"}). In contrast, PD-L1 expression did not increase on B cells, nor did B cells expand after DNP treatment ([Figure 4D](#F4){ref-type="fig"}). Myeloid (CD11b^+^) cells, as well as many CD11b^+^ and CD11b^neg^ DCs, also expressed elevated PD-L1 and expanded following DNP treatment ([Figures 4F--H](#F4){ref-type="fig"}). DNP treatment did not enhance MHCII levels significantly on APCs during EAE ([Supplemental Figure 2](#SM1){ref-type="supplementary-material"}), though even in naïve mice CD19^+^ DCs expressed the highest levels of MHCII, consistent with the mature APC status of this discrete DC subset ([@B20]). Thus, DNP treatment promoted regulatory functions and expansion of DCs but not B cells in mice with EAE.

![DNPs enhance maturation and expansion of tolerogenic APCs expressing PD-L1. EAE was induced in B6 (WT), and experimental groups were treated with either DNP or its vehicle (Veh; 5% glucose) from day 11--21, every other day. On day 22 splenocytes were harvested and stained for CD11c, CD11b, CD19, and PDL1, and analyzed by flow cytometry. Gating strategy and percentages of the populations **(A,E)** analyzed for PDL1. Percentages of different populations of DCs and monocytes expressing PDL1 and the levels of PDL1 expression are shown **(B--D,F--H)**. Statistical significance was determined by two tailed unpaired Student\'s *t*-test; NS, not significant; \**p* \< 0.05; \*\**p* \< 0.01.](fimmu-11-01256-g0004){#F4}

Trp Depletion and AhR Signaling Are Dispensable for Therapeutic Responses After STING Activation
------------------------------------------------------------------------------------------------

IDO activity depletes Trp to induce the integrated stress response (ISR) driven by ribosomal GCN2 kinase, which shuts down most protein synthesis but induces C/EBP homologous protein (CHOP) expression ([@B21]). The ISR blocks effector T cell responses, activates Tregs and suppresses pro-inflammatory IL-6 production by plasmacytoid DCs (pDCs) to suppress immunity ([@B22], [@B23]). Previous reports showed that GCN2 is not required for EAE progression but is required for partial EAE remission to manifest after peak disease ([@B24], [@B25]). We tested if GCN2 and CHOP were required for therapeutic responses to manifest after STING agonist treatments. Therapeutic responses to cGAMP were comparable in WT and GCN2-deficient (GCN2-KO) mice ([Supplemental Figure 3A](#SM1){ref-type="supplementary-material"}), indicating that GCN2 is not essential for therapeutic responses following STING activation to boost IDO activity. Therapeutic responses to DNPs were also comparable in CHOP-KO and WT mice ([Supplemental Figure 3B](#SM1){ref-type="supplementary-material"}). These outcomes indicate that GCN2 and CHOP are both dispensable for therapeutic responses following STING activation.

Some Trp metabolites such as kynurenine (Kyn), suppress immunity via AhR signaling ([@B26], [@B27]). Previous reports showed that AhR gene ablation had minor or no significant effects on EAE susceptibility, while treatments to block AhR signaling suppressed EAE in WT mice ([@B28]--[@B32]). Prompted by this prior work, we tested if AhR signaling mediated therapeutic responses to STING agonists. Mice were given the AhR antagonist drug CH223191 (CH) at optimal doses (5 mg/kg) shown to block AhR signaling effectively in mice ([@B30], [@B33]--[@B35]). CH treatments were administered daily from EAE onset (day 11). Therapeutic responses to cGAMP were comparable in the presence or absence of CH co-treatments ([Supplemental Figure 3C](#SM1){ref-type="supplementary-material"}), suggesting that AhR signaling is dispensable for therapeutic responses induced by cGAMP.

Manipulating Trp Catabolism Potentiates Therapeutic Responses to DNPs
---------------------------------------------------------------------

In addition to immunosuppressive Trp metabolites, cells expressing IDO1 may produce neuroactive Trp metabolites that exacerbate comorbidities such as pain, depression, and fatigue in patients with MS and other neuroinflammatory syndromes ([@B36]--[@B38]). Quinolinic acid (QA) is a N-methyl-D-aspartate (NMDA) receptor agonist and sustained production of neuro-excitatory QA in the central nervous system (CNS) causes neuronal injury. Another Trp catabolite, kynurenic acid (KA), antagonizes NMDA receptor signaling and the KA:QA balance is a pivotal factor modulating neurologic comorbidities ([@B39]). Since increased IDO activity may have neurologic consequences such as increased nociception ([@B40]), we examined how drugs that block production of neuroactive QA or KA impact therapeutic responses to DNPs in the EAE model. As depicted in [Figure 5A](#F5){ref-type="fig"}, kynurenine aminotransferase-II (KatII) converts Kyn into KA and 3-hydroxyanthranilic acid (HAA) dioxygenase (HAAO) converts HAA into QA. The KatII inhibitor PF-04859989 (PF) had no significant impact on EAE progression or clinical severity when applied at EAE onset ([Figure 5B](#F5){ref-type="fig"}). Remarkably, when combined PF and DNP treatments were administered at EAE onset most mice showed no symptoms of EAE (mean score \<0.2) during or after treatments ([Figure 5B](#F5){ref-type="fig"}). Therapeutic responses to combined PF and DNPs were significantly better than responses to DNPs (mean score 1). Thus, PF and DNP co-treatments suppressed EAE progression in the majority of mice, with mild symptoms persisting in only a few mice in this group. Similar outcomes were observed in mice co-treated with an HAAO inhibitor, 4-chloro-3-hydroxyanthranilic acid (4Cl-HAA), though 4Cl-HAA monotherapy slowed EAE progression significantly but did not prevent EAE progression ([Figure 5C](#F5){ref-type="fig"}). Thus, KatII inhibition synergized with DNP treatments while HAAO inhibition supplemented therapeutic responses to DNPs to suppress EAE progression. Thus, STING activation to boost IDO activity in the presence of KatII or HAAO inhibitors are effective strategies to suppress EAE progression.

![Manipulating the IDO pathway reinforces therapeutic responses to DNP treatments. **(A)** The kynurenine pathway. **(B,C)** B6 (WT) mice were treated with DNPs or Vh (glucose 5%), as described previously. Other groups received DNPs and drugs that inhibit KatII (**B**; PF-04859989 daily from day 11--22, 40 mg/kg, i/p), or HAAO (**C**; 4-chloro-3-hydroxyanthranilic acid daily from day 11--21, 125 mg/kg, i/p). Mice were monitored and EAE clinical scores were recorded. Data were analyzed by two-way ANOVA. Experiments were repeated once (*n* = 8--10). NS, not significant; \**p* \< 0.05; \*\**p* \< 0.01; \#*p* \< 0.0001.](fimmu-11-01256-g0005){#F5}

Targeted metabolomics (LC-MS/MS) analyses ([@B41], [@B42]) of brain tissues taken at peak EAE severity (day 14, 3 h after final treatments) revealed that DNP treatments boosted brain Kyn, relative to levels in mice with EAE, and that increased brain Kyn correlated with reduced EAE severity ([Supplemental Figure 4A](#SM1){ref-type="supplementary-material"}). Elevated Kyn was also detected in spleen and serum of DNP-treated mice with EAE (data not shown) confirming that DNPs boost IDO activity systemically. However, DNP treatments reduced brain IDO expression in neurons of MOG-immunized mice ([@B10]), suggesting that increased brain Kyn in DNP-treated mice may be generated in non-CNS tissues and crosses the blood-brain barrier. DNP treatments reduced brain 3HAA levels significantly ([Supplemental Figure 4B](#SM1){ref-type="supplementary-material"}) and boosted brain 3HK levels, albeit not significantly ([Supplemental Figure 4C](#SM1){ref-type="supplementary-material"}), while brain KA levels were unaffected by EAE induction or DNP treatments ([Supplemental Figure 4D](#SM1){ref-type="supplementary-material"}). Co-treatment with KatII inhibitor (PF) blocked DNP-induced increase in brain Kyn, while brain Kyn levels were still elevated in mice co-treated with HAAO inhibitor (4Cl-HAA) and DNPs ([Supplemental Figure 4A](#SM1){ref-type="supplementary-material"}). Further analyses of metabolomics data provided no fresh insights into underlying metabolic processes that explain substantial differences in EAE severity in distinct treatment groups.

Discussion {#s4}
==========

Previously, we showed that DNPs and a bacterial CDN, cyclic diguanyl monophosphate (cdiGMP), activated STING to enhance IDO-dependent regulatory functions of splenic DCs and suppress antigen induced arthritis (AIA) and EAE in mice ([@B9], [@B10], [@B12]). In this study, we further dissect critical pathway components that promote therapeutic responses to STING agonists in the EAE model and show that drugs targeting KatII or HAAO reinforce therapeutic responses to DNPs to suppress EAE progression.

The finding that the cytosolic DNA sensor cGAS promotes therapeutic responses and is required to induce IDO after DNP treatment reveals that cGAS senses DNP cargo DNA to activate STING/IFN-I signaling in DCs competent to express IDO and suppress autoimmunity. STING also promoted tolerogenic responses that attenuated autoimmune lupus progression in susceptible MRL^lpr^ mice, suggesting that cytosolic DNA sensors promote tolerogenic responses that slow lupus progression in this model ([@B7]), though specific requirements for cGAS or IDO to promote tolerogenic responses were not addressed in this study. STING agonists also induced tolerogenic responses that promoted Lewis Lung Carcinoma (LLC) growth in mice by stimulating IDO activity in inflamed lymph nodes draining sites of tumor growth, though cGAS was not essential to induce IDO1 in the LLC model ([@B8]). In contrast, STING agonists incited potent anti-tumor responses in mice bearing more immunogenic B16 melanomas ([@B4]). Opposing outcomes in distinct tumor models emphasize that STING signaling may stimulate or suppress immunity. Elevated IDO activity is a common immune checkpoint in cancer ([@B43]), reinforcing the paradigm that boosting IDO activity protects inflamed tissues from immune-mediated destruction. On the other hand, cytosolic DNA sensing by cGAS to activate STING incited anti-viral immunity, spontaneous autoimmunity in mice with defective DNA catabolizing enzymes and anti-tumor immunity ([@B44]--[@B48]). How DNA from cellular, microbial or artificial sources incites diametric tolerogenic or immunogenic responses is unclear. Differential DNA uptake and sensing by distinct cell types in different tissues may be key factors driving diametric immune responses to DNA in different inflammatory settings. Sustained tissue re-modeling and local inflammation enhance cell death and dying cells promote potent tolerogenic responses, in part because DNA from dying cells is sensed to induce IDO1 and suppress immunity and autoimmunity ([@B12], [@B49], [@B50]). Intra-tumoral injection of synthetic CDNs was essential to incite robust anti-tumor responses to immunogenic B16 melanomas ([@B4]). In contrast, systemic administration of STING agonists was necessary to induce tolerogenic responses ([@B9], [@B10], [@B12]). These findings suggest that circulating STING agonists and dying cells are sensed to induce tolerogenic processes that protect tissues from immune-mediated attack, while DNA sensing to activate STING in inflamed tissues may incite immunogenic or tolerogenic responses that protect against infections or promote tumor growth, respectively. Previously, we identified splenic myeloid (CD11b^+^) DCs as cells uniquely competent to incite IDO1-dependent tolerogenic responses by ingesting and sensing DNP cargo DNA or CDNs to activate STING/IFN-I signaling and induce specialized splenic DCs to express IDO1 ([@B12]). Thus, splenic myeloid DCs may be pivotal cells that sense ingested DNA and cGAMP to generate robust tolerogenic responses that prevent EAE progression.

PD-1/PD-L signaling drives potent tolerogenic responses that suppress effector T cells and activate Tregs in multiple settings ([@B51]). Therapeutic responses to DNPs in the EAE model were partially dependent on PD-1 and fully dependent on PD-L1 and PD-L2, respectively, while therapeutic responses to cGAMP were abolished in mice lacking PD-1 or PD-L1. It is unclear how PD-1 independent therapeutic responses to DNPs manifest but DNPs contain the cationic polymer polyethylenimine that stimulates innate immune signaling via TLR5 ([@B52]), while cGAMP targets STING only. STING agonist treatments enhanced the numbers of splenic DCs (CD11c^+^) and myeloid (CD11b^+^) cells expressing PD-L1 and PD-L1 levels expressed by these cells, suggesting that DCs and myeloid antigen presenting cells (APCs) suppress T cell responses driving EAE. Potential roles for autoreactive B cells in MS immunopathology have been proposed because B cell depleting anti-CD19 mAbs alleviated MS in some patients ([@B53]). Discrete B cell subsets also promote or regulate EAE in mice ([@B54], [@B55]). In mice, a discrete subset of marginal zone DCs co-expressing the B cell marker CD19 (CD19^+^ DCs) are uniquely competent to express IDO1 and become potent regulatory APCs ([@B19]). CD19^+^ DCs expressing IDO1 suppress T cell responses and activate Tregs to block their conversion into T~H~17 T cells. Phenotypic overlaps between CD19^+^ DCs and B cells may explain why some 'B cell' subsets regulate EAE. CD19^+^ DCs expressing IDO1 also expanded in spleens of aged lupus-prone Nba2 mice and during chronic retroviral infections in mice ([@B40], [@B56]). Thus, regulatory B cell subsets, CD19^+^ DCs expressing IDO1 and other regulatory APCs may contribute to therapeutic responses to STING agonists that suppress EAE.

Defects in PD-1/PD-L signaling did not compromise IDO1 induction following STING activation, indicating that the PD-1/PD-L and IDO1 pathways act independently to promote tolerogenic responses in response to STING activation. In contrast, PD-1 signaling was essential to induce IDO1 and tolerogenic responses following TLR9 ligation ([@B15]). Like STING agonists, TLR9 ligands stimulate IFN-I production by DCs and IFN-I induces IDO ([@B17], [@B19]). Ablating CD19 or the PD-1/PD-L pathway abolished IDO induction in CD19^+^ DCs and tolerogenic responses following TLR9 ligation and instead elicited immunogenic responses. Thus, CD19^+^ DCs are pivotal cells controlling responses to TLR9 ligands and PD-1/PD-L interactions between Tregs (or T cells) and CD19^+^ DCs are necessary to induce CD19^+^ DCs to express IDO1 and acquire tolerogenic phenotypes in this setting. As IDO induction after STING activation was not PD-1/PD-L dependent, signals from Tregs or T cells expressing PD-1 to induce CD19^+^ DCs to express IDO1 are not required for tolerogenic responses to STING agonists. It is unclear why PD-1/PD-L interactions were not required to induce IDO1 in CD19^+^ DCs following STING activation. However, downstream interactions between regulatory APCs or other cells types expressing PD-1 ligands and T cells or Tregs expressing PD-1 are essential to promote tolerogenic responses that suppress EAE.

IDO activity inhibits T cell responses via two metabolic pathways, Trp depletion to activate the GCN2/CHOP-dependent ISR and Trp catabolite production ([@B11], [@B57]). HAA suppresses T cell responses by inhibiting PDK1-mediated NF-kB activation to promote T cell apoptosis ([@B58]), while Kyn and KA are natural AhR ligands and AhR signaling regulates T cell responses ([@B26], [@B27], [@B59]). Therapeutic responses to DNPs were unaffected by GCN2 ablation while therapeutic responses to cGAMP were unaffected by AhR signaling blockade, indicating that neither pathway is essential for therapeutic responses to STING agonists. Also, CHOP ablation had no major impact on therapeutic responses to DNPs. Though CHOP is a GCN2 target, other stress pathways can activate CHOP and these alternative pathways may mediate therapeutic effects. The ISR and AhR signaling may be dispensable for therapeutic responses to STING agonists because each pathway compensates for loss of the other making each pathway functionally redundant for therapeutic responses. Alternatively, other metabolic effects of elevated IDO activity such as altered redox potentials ([@B60]) may influence EAE pathogenesis and therapeutic responses to STING agonists.

Two well-characterized and well-tolerated drugs that inhibit KatII ([@B61]--[@B63]) or HAAO ([@B64]--[@B66]) were used to assess metabolic requirements that promote therapeutic responses to DNPs downstream of IDO. Combining either drug with DNPs prevented EAE progression, even after treatments ended. Stable disease control is difficult to achieve in the EAE model, as depots of autoantigen and adjuvant (MOG/CFA) with potent encephalitogenic properties persist at sites of immunization. As KatII converts Kyn into KA and HAAO converts HAA into QA ([Figure 5A](#F5){ref-type="fig"}), our findings suggest that KatII and HAAO activity may attenuate therapeutic responses to DNPs by consuming Trp metabolites that mediate immune suppression such as Kyn, 3-HK and HAA. Previous studies showed that HAA (or a synthetic HAA derivative) attenuated EAE, though therapeutic responses were weak ([@B67], [@B68]). Thus, boosting HAA production and blocking HAA consumption in tissues may be more effective than administering exogenous HAA. Reduced KA or QA production may also contribute to robust therapeutic responses after DNP treatment. HAAO inhibition may attenuate neurologic comorbidities by reducing production of neuroexcitatory QA, though blocking KA production may potentiate neurologic comorbidities since KA antagonizes QA-mediated neuronal stimulation via NMDA. To further evaluate metabolic changes in the Kyn pathway we conducted metabolomics analyses of tissues (brain, spleen) and serum samples. Outcomes confirmed that DNPs boost IDO activity systemically and suggest that Kyn generated in non-CNS tissues following DNP treatment may cross the blood-brain barrier in DNP-treated mice. However, no additional insights were forthcoming, highlighting the technical difficulty of identifying critical metabolic changes in small cohorts of physiologic cells that drive therapeutic responses using metabolomics analyses. These points notwithstanding, our findings show that boosting kinetic flux through the Kyn pathway and manipulating the balance of alternative Trp metabolism pathways downstream of IDO have profound effects on immunologic responses to STING agonists that promote durable therapeutic responses in the EAE model.

Abnormal levels of KA and QA were detected in serum of MS patients and abnormalities in Kyn pathway metabolism may be associated with clinical MS subtypes, and may serve as potential biomarkers of MS stage and progression ([@B38], [@B69], [@B70]). As we depict in the graphic hypothesis ([Figure 6](#F6){ref-type="fig"}) summarizing findings reported here, and in a previous study using the same model ([@B10]), the Kyn pathway has a complex role in immunologic and neurologic processes driving autoimmunity and comorbidities during EAE disease progression and responses to STING agonist treatments to alleviate EAE. Sustained IDO expression in CNS tissues contributes to EAE pathogenesis because Trp metabolites such as QA may cause neuro-inflammatory injury leading to psychotic disorders ([@B71]). Previously, we reported that EAE induction *per se* stimulates IDO1 expression by CNS neurons, which may promote neuronal injury ([@B10]). Paradoxically, DNP treatments abolished IDO expression in CNS neurons, possibly because increased IDO activity in lymphoid tissues blocked expansion and activation of MOG-specific T cells that would otherwise infiltrate CNS tissues and induce local IDO expression, for example by secreting IFNγ. Several Trp metabolites, including Kyn, KA, 3-HK and HAA, have been implicated in immune regulation as they diminish TCR signaling and enhance AhR signaling in T cells and other immune cells ([@B27], [@B72]). The Trp catabolite xanthurenic acid (XA) may also suppress T cell responses after DNP treatment, as XA inhibits synthesis of the enzyme cofactor tetrahydrobiopterin (BH4) by activated T cells and BH4 is essential for T cell clonal expansion ([@B73]). Another mechanism that may promote therapeutic responses to STING agonists is that HAA induces CNS astrocytes to express HO-1, which generates compounds with anti-inflammatory and cytoprotective properties ([@B74]). Further studies to identify specific cell types that produce and consume particular Trp metabolites, determine the tissue locations of such cells and define targets of Trp metabolites will be key to understanding how increased metabolic flux through the Kyn pathway contributes to immunologic and neurologic processes during disease progression and comorbidities, as well as responses to therapy. In summary, our findings reveal that boosting IDO activity and manipulating the IDO pathway is an effective therapeutic strategy to treat neuro-inflammatory autoimmune syndromes.

![Graphical hypothesis. MOG immunization generates MOG-specific effector T cells that migrate to the CNS where they cause neuronal injury and induce neurons to express IDO1 and produce neurotoxic Trp catabolites such as QA (green highlights). STING agonists induce DCs in lymphoid tissues to express IDO1 and produce Trp catabolites that suppress generation of MOG-specific T cells (red highlights). Manipulating Trp catabolism to enhance production of immune suppressive catabolites and block production of neurotoxic catabolites may be an effective strategy to boost tolerogenic responses that promote stable EAE remission and alleviate neurologic comorbidities.](fimmu-11-01256-g0006){#F6}
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